GlaxoSmithKline Articles
US rheumatologists express significant interest in Benlysta, the first novel drug for lupus in decades
16 June 2010
US FDA approves GlaxoSmithKline’s Jalyn for symptomatic BPH; fast tracks Genzyme’s MS drug alemtuzumab
15 June 2010
GlaxoSmithKline drives into Latin America’s branded generics sector, buying Labs Phoenix for $253 million
11 June 2010
GlaxoSmithKline gets negative NICE appraisal for Revolade; another attack on safety of Avandia
11 June 2010
Good and bad news for Human Genome Sciences, as it files Benlysta BLA but mapatumumab disappoints in Ph II
11 June 2010
Merck Serono resubmits cladribine as a potential MS therapy in USA; GSK/HGS file Benlysta in Europe
8 June 2010
German Court revokes GlaxoSmithKline Viani/Advair patent; Company identifies new malaria leads
21 May 2010
Disappointments for NicOx, as FDA panel rejects naproxcinod, and GlaxoSmithKline, which halts Promacta trial
13 May 2010
US Coalition for Vaccine Safety calls on FDA to immediately suspend all contaminated rotavirus vaccines
11 May 2010
GlaxoSmithKline 1st-qtr 2010 EPS leaps 18%, driven by better-than-expected swine flu vaccine sales and Asia/emerging markets
29 April 2010
Europe’s CHMP updates on pandemic vaccines, backs use extensions for Reyataz and RoActemra, concludes Seroquel XR arbitration
26 April 2010
Human Genome/GlaxoSmithKline lupus drug Benlysta disappoints in Ph III; Updates on Seattle Genetics and Ligand milestones
21 April 2010
BioMarin launches LEMS drug Firdapse in European Union; and Genmab gets conditional approval for Arzerra
20 April 2010
US FDA approves Strativa’s Oravig, triggering a $20 million milestone for France’s BioAlliance; Agency could put hold on GSK
19 April 2010
EPO Rules European Patent for XenoPort’s XP13512 is valid; Almirall grants Eisai marketing rights to cinitapride in China
16 April 2010
GlaxoSmithKline sees UK govt order for pandemic vaccine slashed; enters malaria vaccine deal with Crucell
7 April 2010
GlaxoSmithKline offers free vaccines to uninsured US adults; re-submits Avodart to FDA
30 March 2010
Poland’s Bioton and Polpharma investigating the possibility of a merger; BMI sees pharma market attractive to MNCs
25 March 2010
Pfizer and GlaxoSmithKline pledge long-term supply of pneumococcal vaccines to world's poorest countries at big discount
24 March 2010
US FDA recommends temporary suspension of GlaxoSmithKline’s Rotarix due to extraneous virus
23 March 2010
Majority of researchers supporting GlaxoSmithKline’s Avandia “had ties to the firm;” Takeda pulls SR-Competact MAA
22 March 2010
US President and FTC still believe legislation banning pay-to-delay settlements needed
19 March 2010
Leading 20 cancer drugs to generates sales of $1 billion in Australia by 2018; says Datamonitor study
14 March 2010
Drug's effect on reduction of new hip fractures is greatest influence on Rxing decisions, says DR report
5 March 2010
AstraZeneca says it will shed 1,000 jobs in the UK, with 1,800 R&D posts to go in total
3 March 2010
Belgium’s UCB posts disappointing 2009 results, but projects better future based on newer drugs
3 March 2010
Actelion shares plunge as Tracleer fails to meet primary endpoint in idiopathic pulmonary fibrosis
2 March 2010
Ranbaxy back in black in fourth quarter as US sales soar
26 February 2010
GlaxoSmithKline responds to critical US Senate Finance Committee, defending safety of its Avandia
25 February 2010
AstraZeneca settles over transfer pricing in UK, agreeing to pay £505 million; GSK slumps on Avandia news
23 February 2010
GlaxoSmithKline “knew about heart attack risks of Avandia,” claim US Senators, who also slam FDA
22 February 2010
Europe’s CHMP backs Sanofi Pasteur’s Humenza and GSK’s Votrient; gives opinions on other products
22 February 2010
US FDA calls for new safety controls on long-acting asthma drugs that could hit sales potential
19 February 2010
Soaring Tracleer sales boost Actelion’s 2009 financial results
19 February 2010
GlaxoSmithKline/XenoPort get negative response from USA’s FDA for Horizant; Merck & Co won’t file for vicriviroc now
18 February 2010
New Ph III data shows Merck & Co's Gardasil was effective against anal disease caused by HPV 6,11,16, and 18
18 February 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
Neuropathic pain - brighter future for pipeline drugs with market to double in value to $5.2 billion
17 February 2010
Vernalis to re-acquire EU frovatriptan royalties; Isogenica gains rights to commercialize drugs with MRSA potential
15 February 2010
AstraZeneca’s CEO defends company’s stance in Bloomberg interview
15 February 2010
GlaxoSmithKline debuts “CARES by GSK” in USA to improve patient access to its oncology and specialty medicines
12 February 2010
UK Appeal Court invalidates HGS/GlaxoSmithKline lupus drug patent; Simcere cleared to manufacture and sell zanamivir in China
11 February 2010
Merck & Co’s new combo asthma drug expected to garner peak year sales of over $250 million
10 February 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
GSK launches new specialist rare diseases R&D unit; names new president for GSK Japan
5 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
Austria’s Apeiron sells rights to early-stage lung disease drug to GlaxoSmithKline for as much as $332 million
4 February 2010
13.7% growth for Indian pharma recorded 13.7%to $9.43 billion in first three quarters of fiscal 2009-10
4 February 2010
Watson gains exclusive US rights to HRA Pharma’s ulipristal and Abbott makes deal with Fabre for MAb
2 February 2010
US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts
1 February 2010
AstraZeneca to cut another 8,000 jobs as part of $1.8 billion cost-cutting program; unveils new R&D model
29 January 2010
New data on rotavirus vaccine from Mexico and Africa show lifesaving impact and effectiveness in the developing world
29 January 2010
AstraZeneca sees strong earnings and revenue growth in2009 but a slowdown in 4th qtr
28 January 2010
EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products
22 January 2010
GSK‘s “Open Innovation” strategy to help deliver medicines to people in the world's poorest countries
21 January 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
Republican victory in Massachusetts a blow for Obama health reform plans; not a happy first anniversary present
20 January 2010
Philippines seeks more voluntary drug price reductions
19 January 2010
FDA warns US consumers about counterfeit weight-loss drug Alli
19 January 2010
WHO’s pandemic advisor strongly denies industry influence in “false flu pandemic fiasco;” GSK says same
18 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Merck & Co aims to expand Gardasil usage to boost flagging sales
18 January 2010
EU action on pharma patent “pay-to-delay” settlements - a legal opinion; US FTC also to review the subject
13 January 2010
Roche enters COPD sector with 400 million-plus-euro deal with Galapagos and antibody accord with AnaptysBio
12 January 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
